Designer antigens for elicitation of broadly neutralizing antibodies against HIV

Kok, T, Gaeguta, A, Finnie, J, Gorry, P, Churchill, M and Li, P 2014, 'Designer antigens for elicitation of broadly neutralizing antibodies against HIV', Clinical and Translational Immunology, vol. 3, no. 9, e24, pp. 1-6.


Document type: Journal Article
Collection: Journal Articles

Title Designer antigens for elicitation of broadly neutralizing antibodies against HIV
Author(s) Kok, T
Gaeguta, A
Finnie, J
Gorry, P
Churchill, M
Li, P
Year 2014
Journal name Clinical and Translational Immunology
Volume number 3
Issue number 9
Article Number e24
Start page 1
End page 6
Total pages 6
Publisher Australasian Society for Immunology
Abstract Broadly neutralizing antibodies (bNAbs) are a consistent protective immune correlate in human immunodeficiency virus (HIV) patients as well as in passive immunotherapy studies. The inability to elicit bNAbs is the core reason underlining the repeated failures in traditional HIV vaccine research. Rare monoclonal bNAbs against HIV, however, have been produced. The significance of producing and studying more monoclonal bNAbs against HIV is underlined by its capability of defining critical epitopes for antigen designs aimed at the development of a serum-neutralizing HIV vaccine. In this regard, traditional antigen preparations have failed. There is a need to clearly advocate the concept, and systematic study, of more sophisticated 'designer antigens' (DAGs), which carry epitopes that can lead to the elicitation of bNAbs. Using an extremely efficient cell-to-cell HIV infection model for the preparation of HIV prefusion intermediates, we have investigated a novel and systematic approach to produce (not screen for) potential bNAbs against HIV. We have established the concept and the experimental system for producing formaldehyde-fixed HIV DAGs that carry temperature-arrested prefusion intermediates. These prefusion intermediates are structures on the cell surface after viral attachment and receptor engagement but before fully functional viral entry. Using defined HIV prefusion DAGs, we have produced monoclonal antibodies (mAbs) specific to novel epitopes on HIV prefusion intermediates. These mAbs do not react with the static/native surface HIV or cellular antigens, but react with the DAGs. This is a paradigm shift from the current mainstream approach of screening elite patients' bNAbs.
Subject Infectious Diseases
DOI - identifier 10.1038/cti.2014.22
Copyright notice © 2014 Australasian Society for Immunology Inc. All rights reserved. This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
ISSN 2050-0068
Versions
Version Filter Type
Altmetric details:
Access Statistics: 71 Abstract Views  -  Detailed Statistics
Created: Tue, 29 Sep 2015, 10:33:00 EST by Catalyst Administrator
© 2014 RMIT Research Repository • Powered by Fez SoftwareContact us